BioCryst Pharmaceuticals Given “Positive” Rating at Bank of America (BCRX)
The analysts wrote, “As we had expected, BCRX announced positive proof of concept data for its oral kallikrein inhibitor, ’4161 in HAE prophylaxis. HAE attack rate/week was reduced by 35% (0.82 vs. pbo of 1.27, p<0.001), which fell short of Cinryze’s 52% reduction in ph 3 (12 wk study) but we note differences in study design and duration (four weeks for BCRX). While compliance was 98% with four oral pills taken 3x/day, we believe the clinical trial setting and short four week duration allowed for higher compliance than likely seen in a real world setting. “We raised our prob. of both US and ex-US approvals to 50% (from 35%), but lowered our peak WW patient estimates from 1750 to 1500 based on our view that ’4161′s efficacy is modest, could trend lower with lower compliance, and has significant patient-to-patient variability (below). These changes raised our PO to $9 (from $8). We continue to see potential for significant upside if one of BCRX’ next generation one pill once/day candidates shows better bioavailability. BCRX plans to commence the OPuS-2 phase 2b trial later in 2014.”
Other equities research analysts have also recently issued reports about the stock. Analysts at Brinson Patrick initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, April 14th. They set an “outperform” rating and a $15.00 price target on the stock. Separately, analysts at HC Wainwright initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, March 10th. They set a “buy” rating and a $21.00 price target on the stock. Finally, analysts at MLV & Co
raised their price target on shares of BioCryst Pharmaceuticals from $9.00 to $15.00 in a research note on Tuesday, March 4th. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $17.57.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 3.20% during mid-day trading on Wednesday, hitting $9.6701. 486,416 shares of the company’s stock traded hands. BioCryst Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $13.33. The stock has a 50-day moving average of $8.58 and a 200-day moving average of $8.97. The company’s market cap is $580.8 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings data on Thursday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was down 2.8% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.